InnoCare has a strong team of scientists and professionals, including an elite Scientific Advisory Board, dedicated to defeating diseases and pushing the boundaries of innovation. They hold multiple patents and have a rich product pipeline targeting liquid tumors, solid tumors, and autoimmune diseases. InnoCare's commercial drug candidate is Orelabrutinib, and they have 11 drug candidates in clinical stages and 5 in IND-enabling stages. With near 900 employees and global sites in China and the United States, InnoCare aims to become a world-class biopharmaceutical leader to address unmet medical needs globally.